Prediction of the VeriStrat test in first-line therapy of pemetrexed-based regimens for advanced lung adenocarcinoma pat
- PDF / 776,851 Bytes
- 7 Pages / 595.276 x 790.866 pts Page_size
- 37 Downloads / 168 Views
PRIMARY RESEARCH
Cancer Cell International Open Access
Prediction of the VeriStrat test in first‑line therapy of pemetrexed‑based regimens for advanced lung adenocarcinoma patients Bo Jia1†, Zhi Dong2†, Di Wu3†, Jun Zhao1, Meina Wu1, Tongtong An1, Yuyan Wang1, Minglei Zhuo1, Jianjie Li1, Yang Wang3, Jie Zhang3, Xinghui Zhao1, Sheng Li1, Junfeng Li1, Menglei Ma1, Chen Chen4, Xue Yang1, Jia Zhong1, Hanxiao Chen1, Jingjing Wang1, Yujia Chi1, Xiaoyu Zhai1, Song Cui5, Rong Zhang5, Qingwei Ma5, Jian Fang3* and Ziping Wang1*
Abstract Background: Although advanced non-squamous non-small cell lung cancer (NSCLC) patients have significantly better survival outcomes after pemetrexed based treatment, a subset of patients still show intrinsic resistance and progress rapidly. Therefore we aimed to use a blood-based protein signature (VeriStrat, VS) to analyze whether VS could identify the subset of patients who had poor efficacy on pemetrexed therapy. Methods: This study retrospectively analysed 72 advanced lung adenocarcinoma patients who received first-line pemetrexed/platinum or combined with bevacizumab treatment. Results: Plasma samples from these patients were analysed using VS and classified into the Good (VS-G) or Poor (VS-P) group. The relationship between efficacy and VS status was further investigated. Of the 72 patients included in this study, 35 (48.6%) were treated with pemetrexed plus platinum and 37 (51.4%) were treated with pemetrexed/ platinum combined with bevacizumab. Among all patients, 60 (83.3%) and 12 (16.7%) patients were classified as VS-G and VS-P, respectively. VS-G patients had significantly better median progression-free survival (PFS) (Unreached vs. 4.2 months; P
Data Loading...
